3,732 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,732 shares of the company’s stock, valued at approximately $430,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Algert Global LLC acquired a new position in Neurocrine Biosciences during the third quarter worth $2,116,000. Cerity Partners LLC boosted its holdings in Neurocrine Biosciences by 42.4% in the third quarter. Cerity Partners LLC now owns 39,024 shares of the company’s stock valued at $4,496,000 after acquiring an additional 11,622 shares during the last quarter. HealthInvest Partners AB boosted its stake in shares of Neurocrine Biosciences by 156.5% in the 3rd quarter. HealthInvest Partners AB now owns 60,607 shares of the company’s stock valued at $6,983,000 after purchasing an additional 36,977 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Neurocrine Biosciences by 4.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 163,054 shares of the company’s stock valued at $18,787,000 after acquiring an additional 7,069 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $1,001,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $125.65 on Monday. Neurocrine Biosciences, Inc. has a 1 year low of $110.52 and a 1 year high of $157.98. The stock’s fifty day moving average price is $118.62 and its two-hundred day moving average price is $131.94. The company has a market cap of $12.72 billion, a P/E ratio of 33.69 and a beta of 0.35.

Analysts Set New Price Targets

Several analysts recently commented on the company. BMO Capital Markets dropped their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Robert W. Baird upped their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price target for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Barclays dropped their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.